Astellas CFO Pushes Finance Beyond the Spreadsheet in Pharma's AI Era
Atsushi Kitamura has a problem that would make most CFOs nervous: his finance team at Astellas Pharma is being asked to do things that have nothing to do with closing the books.
The Japanese pharmaceutical giant's CFO is reimagining what the finance function actually does—a shift that's less about new software and more about whether finance leaders can credibly weigh in on drug development decisions, not just drug development budgets. It's the kind of role expansion that sounds great in a conference keynote but typically dies in the implementation, buried under month-end close deadlines and audit prep.
What makes Kitamura's approach notable is the timing. Pharma CFOs are caught in a peculiar squeeze: the industry's R&D spending is simultaneously ballooning (because developing drugs is expensive and getting more so) and under intense scrutiny (because investors want to see returns, not just pipeline promises). The traditional CFO playbook—track spending, report results, occasionally say "no"—doesn't cut it when the CEO is asking whether to kill a Phase 2 trial or double down.
Kitamura's answer, based on his remarks at a CFO Leadership Council forum, is to make finance a strategic partner in those decisions rather than the scorekeeper who tallies up the damage afterward. The distinction matters. A scorekeeper tells you what happened. A partner helps you figure out what should happen next.
Here's the thing everyone's missing: this isn't actually about finance people learning science. (Though that helps.) It's about finance people learning to translate scientific uncertainty into investment language that boards and investors can actually use. When a research team says "we think this compound shows promise," someone needs to turn that into "here's what we'd need to see in the next 18 months to justify continued investment, and here's what we do if we don't see it."
That's a finance skill, not a science skill. But it requires finance leaders who are comfortable operating in the gray zone where the data is incomplete and the decisions are judgment calls. Most finance training actively discourages this—we're taught to wait for certainty, to demand proof, to hedge our language until it's meaningless.
The pharmaceutical industry is a particularly brutal testing ground for this expanded CFO role because the stakes are so high and the timelines so long. A bad capital allocation decision in pharma doesn't show up as a bad quarter—it shows up as a failed drug trial three years later, after you've burned through hundreds of millions of dollars. By then, the CFO who approved the spending might not even be at the company anymore.
What Kitamura seems to be arguing for—and this is where it gets interesting for CFOs in other industries—is that finance needs to develop what you might call "forward-looking accountability." Not just tracking what was spent, but actively shaping what gets spent and why, with enough skin in the game that finance owns the outcome, not just the accounting for it.
The practical question for other finance leaders: can your team actually do this? Not in theory, but in practice. Can your FP&A director walk into a product development meeting and credibly challenge assumptions about market size, development timelines, or competitive positioning? Or are they just there to write down the numbers other people give them?
If it's the latter, you're running a 20th-century finance function in an industry that's moving too fast for that to work. And unlike Astellas, you probably don't have the luxury of a multi-billion-dollar market cap to cushion the learning curve.
Responses (0 )